| Target Molecule | Icatibant |
| Synonyms | Firazyr, HOE-140, JE049, Icatibant Acetate |
| CAS Number | 130308-48-4 (free base); 138614-30-9 (acetate salt) |
| Sequence (3-Letter) | H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH |
| Sequence (1-Letter) | (D-Arg)-R-P-Hyp-G-Thi-S-(D-Tic)-Oic-R |
| Molecular Formula | C₅₉H₈₉N₁₉O₁₃S (free base) |
| Molecular Weight | 1304.52 (free base) |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical form), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) for Sterically Hindered Peptidomimetics |
| Modification Options | Conformationally constrained unnatural amino acids (Tic, Oic, Thi, Hyp), D-amino acid substitution, stable isotope labeling (13C, 15N), diastereomer impurity standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and chiral purity confirmation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Icatibant (CAS 130308-48-4) is a synthetic decapeptide peptidomimetic functioning as a selective bradykinin B2 receptor antagonist. Its sequence features extensive non-proteinogenic modifications, including D-Arg, hydroxyproline (Hyp), 3-(2-thienyl)alanine (Thi), D-tetrahydroisoquinoline-3-carboxylic acid (D-Tic), and octahydroindole-2-carboxylic acid (Oic). We target this sequence to supply high-purity reference materials and raw materials for hereditary angioedema and inflammation research.
The inclusion of rigid bicyclic and heterocyclic building blocks (D-Tic, Oic, Hyp, Thi) creates severe steric hindrance during chain elongation, lowering coupling rates and elevating the risk of epimerization. Our peptide synthesis platform applies specialized coupling cocktails, elevated temperature control, and real-time monitoring to ensure high-fidelity assembly without chiral inversion.
Yes. We provide extensive peptide modification services for peptidomimetics. Capabilities include the deliberate synthesis of diastereomers and deletion sequences as critical impurity reference standards, site-specific stable isotope labeling (13C, 15N) for quantitative LC-MS/MS bioanalysis, and fluorescent probes for receptor kinetic assays.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to accelerate complex preclinical and commercial pipelines.
Icatibant (CAS 130308-48-4), historically referenced under code HOE-140 and marketed as Firazyr, is a synthetic decapeptide peptidomimetic operating as a selective, competitive antagonist at the bradykinin B2 receptor. Defined by the sequence H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH, it replaces five of the nine native bradykinin residues with conformationally constrained unnatural amino acids and D-enantiomers. Synpeptide provides comprehensive custom synthesis solutions for this molecule, showcasing our technical expertise in non-standard building block assembly, stereochemical control, and CDMO manufacturing.
Assembling Icatibant presents notable chemical hurdles during solid-phase elongation. Adjacent secondary and heterocyclic amino acids—specifically D-Tic and Oic—induce extreme steric congestion and reduce the nucleophilicity of the growing peptide chain. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols on low-loading resins. By implementing high-efficiency coupling chemistries and precise cycle monitoring, we suppress incomplete coupling and epimerization, delivering raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
Due to the incorporation of multiple rigid unnatural residues and D-amino acids, Icatibant demands rigorous analytical profiling. Diastereomeric impurities arising from partial racemization at chiral centers can alter antagonist potency. Through our peptide modification services, we synthesize deliberate diastereomers, uncyclized variants, and deletion sequences as reference standards for stability-indicating analytical assays. We also offer site-specific stable isotope labeling (13C, 15N) for pharmacokinetic mass spectrometry and fluorescently tagged derivatives for receptor binding studies.
Transitioning a heavily modified peptidomimetic from laboratory-scale synthesis to commercial supply requires robust downstream chemical engineering. The rigid hydrophobic nature of Tic and Oic residues alters solubility and chromatographic retention profiles during scale-up. We execute large-scale peptide synthesis for Icatibant by optimizing preparative HPLC purification and controlled lyophilization. Our facilities accommodate demands from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (providing the pharmaceutical acetate salt form) across all production volumes.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete analytical documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
